Chief Scientific Officer
Curt Bradshaw is co-founder and Chief Scientific Officer of Solstice Biologics and heads its research laboratories. He has more than 22 years of chemistry and drug discovery experience in pharma and biotech, including roles as Vice President Chemistry of CovX developing novel antibody platform technologies (acquired by Pfizer) and tenures at Pfizer, Abbott Laboratories and Ligand Pharmaceuticals. With industry experience ranging from early research and discovery through GMP drug substance manufacturing, Dr. Bradshaw brings a broad background to technology and drug development, and is credited with the discovery of several human clinical stage therapeutics. His scientific expertise in synthetic biologics includes oligonucleotides, peptides, proteins, antibodies, bioconjugation, and chemical development.